Cargando…

Novel Pharmacological Therapies for Management of Chronic Constipation

Chronic constipation is a common health problem that significantly affects the quality of life of patients and impacts in terms of costs; current treatments based on fiber and laxatives cause dissatisfaction to doctors and patients in more than half of the cases. New drugs are now available or in ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Martinez, Marina A., Ortiz-Olvera, Nayeli X., Mendez-Navarro, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Raven Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864180/
https://www.ncbi.nlm.nih.gov/pubmed/24172177
http://dx.doi.org/10.1097/01.mcg.0000436440.05887.02
_version_ 1782295906503098368
author Gonzalez-Martinez, Marina A.
Ortiz-Olvera, Nayeli X.
Mendez-Navarro, Jorge
author_facet Gonzalez-Martinez, Marina A.
Ortiz-Olvera, Nayeli X.
Mendez-Navarro, Jorge
author_sort Gonzalez-Martinez, Marina A.
collection PubMed
description Chronic constipation is a common health problem that significantly affects the quality of life of patients and impacts in terms of costs; current treatments based on fiber and laxatives cause dissatisfaction to doctors and patients in more than half of the cases. New drugs are now available or in very advanced stages of research, with different and innovative mechanisms of action as prucalopride, lubiprostone, and linaclotide. Prucalopride an enterokinetic, is a selective high-affinity 5-hydroxytryptamine (5-HT)(4) receptor agonist of serotonin that increases the peristaltic reflex and the colonic contractions; lubiprostone, a type 2 chlorine channel activator, or linaclotide, a guanylate cyclase-C agonist of enterocytes, both prosecretory agents, stimulate the secretion of fluid within the intestinal lumen. In general, these promising drugs have proven efficacy and safety as a specific therapeutic option in patients with chronic constipation. Yet the solution might not be sufficient for everybody and still without the ideal drug that might be useful in all cases, the pharmacological revolution for colonic motility disorders has arrived.
format Online
Article
Text
id pubmed-3864180
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Raven Press
record_format MEDLINE/PubMed
spelling pubmed-38641802013-12-16 Novel Pharmacological Therapies for Management of Chronic Constipation Gonzalez-Martinez, Marina A. Ortiz-Olvera, Nayeli X. Mendez-Navarro, Jorge J Clin Gastroenterol Clinical Reviews Chronic constipation is a common health problem that significantly affects the quality of life of patients and impacts in terms of costs; current treatments based on fiber and laxatives cause dissatisfaction to doctors and patients in more than half of the cases. New drugs are now available or in very advanced stages of research, with different and innovative mechanisms of action as prucalopride, lubiprostone, and linaclotide. Prucalopride an enterokinetic, is a selective high-affinity 5-hydroxytryptamine (5-HT)(4) receptor agonist of serotonin that increases the peristaltic reflex and the colonic contractions; lubiprostone, a type 2 chlorine channel activator, or linaclotide, a guanylate cyclase-C agonist of enterocytes, both prosecretory agents, stimulate the secretion of fluid within the intestinal lumen. In general, these promising drugs have proven efficacy and safety as a specific therapeutic option in patients with chronic constipation. Yet the solution might not be sufficient for everybody and still without the ideal drug that might be useful in all cases, the pharmacological revolution for colonic motility disorders has arrived. Raven Press 2014-01 2013-12-18 /pmc/articles/PMC3864180/ /pubmed/24172177 http://dx.doi.org/10.1097/01.mcg.0000436440.05887.02 Text en Copyright © 2013 by Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Clinical Reviews
Gonzalez-Martinez, Marina A.
Ortiz-Olvera, Nayeli X.
Mendez-Navarro, Jorge
Novel Pharmacological Therapies for Management of Chronic Constipation
title Novel Pharmacological Therapies for Management of Chronic Constipation
title_full Novel Pharmacological Therapies for Management of Chronic Constipation
title_fullStr Novel Pharmacological Therapies for Management of Chronic Constipation
title_full_unstemmed Novel Pharmacological Therapies for Management of Chronic Constipation
title_short Novel Pharmacological Therapies for Management of Chronic Constipation
title_sort novel pharmacological therapies for management of chronic constipation
topic Clinical Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864180/
https://www.ncbi.nlm.nih.gov/pubmed/24172177
http://dx.doi.org/10.1097/01.mcg.0000436440.05887.02
work_keys_str_mv AT gonzalezmartinezmarinaa novelpharmacologicaltherapiesformanagementofchronicconstipation
AT ortizolveranayelix novelpharmacologicaltherapiesformanagementofchronicconstipation
AT mendeznavarrojorge novelpharmacologicaltherapiesformanagementofchronicconstipation